抗高血压药物与慢性肾脏病分期的变化。

International Journal of Chronic Diseases Pub Date : 2018-02-25 eCollection Date: 2018-01-01 DOI:10.1155/2018/1382705
Marina Komaroff, Fasika Tedla, Elizabeth Helzner, Michael A Joseph
{"title":"抗高血压药物与慢性肾脏病分期的变化。","authors":"Marina Komaroff, Fasika Tedla, Elizabeth Helzner, Michael A Joseph","doi":"10.1155/2018/1382705","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this study is to estimate the change in the relationships between use of five classes of antihypertensive medications and stages of Chronic Kidney Disease (CKD) in American adults treated for hypertension.</p><p><strong>Methods: </strong>The US National Health and Nutrition Examination Survey (NHANES) data sets 1999-2012 were used with the final analytical sample of 3,045 participants. Population prevalence estimates were calculated using the NHANES survey design weights. Inferential analyses were done with binomial logistic regression models.</p><p><strong>Results: </strong>The odds of advanced (3, 4, and 5 combined) versus early CKD stages (1 and 2 combined) were significantly higher among patients treated with Angiotensin Receptor Blockers (ARB) versus those not treated with ARB in 2009-2012 (adjusted odds ratio (95% confidence interval) = 2.52 (1.32-4.80)). From 1999 to 2012, the increase in this relationship was significant (<i>p</i> = 0.0023) for users of ARB polytherapy and in users of ARB in patients with albuminuria (<i>p</i> = 0.0031).</p><p><strong>Conclusion: </strong>Aggressive pharmacological management of hypertension with ARB as add-on therapy may have accelerated kidney damage in American adults. However, prospective longitudinal studies are needed to establish proper temporal sequence in this relationship.</p>","PeriodicalId":13831,"journal":{"name":"International Journal of Chronic Diseases","volume":"2018 ","pages":"1382705"},"PeriodicalIF":0.0000,"publicationDate":"2018-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845497/pdf/","citationCount":"0","resultStr":"{\"title\":\"Antihypertensive Medications and Change in Stages of Chronic Kidney Disease.\",\"authors\":\"Marina Komaroff, Fasika Tedla, Elizabeth Helzner, Michael A Joseph\",\"doi\":\"10.1155/2018/1382705\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The goal of this study is to estimate the change in the relationships between use of five classes of antihypertensive medications and stages of Chronic Kidney Disease (CKD) in American adults treated for hypertension.</p><p><strong>Methods: </strong>The US National Health and Nutrition Examination Survey (NHANES) data sets 1999-2012 were used with the final analytical sample of 3,045 participants. Population prevalence estimates were calculated using the NHANES survey design weights. Inferential analyses were done with binomial logistic regression models.</p><p><strong>Results: </strong>The odds of advanced (3, 4, and 5 combined) versus early CKD stages (1 and 2 combined) were significantly higher among patients treated with Angiotensin Receptor Blockers (ARB) versus those not treated with ARB in 2009-2012 (adjusted odds ratio (95% confidence interval) = 2.52 (1.32-4.80)). From 1999 to 2012, the increase in this relationship was significant (<i>p</i> = 0.0023) for users of ARB polytherapy and in users of ARB in patients with albuminuria (<i>p</i> = 0.0031).</p><p><strong>Conclusion: </strong>Aggressive pharmacological management of hypertension with ARB as add-on therapy may have accelerated kidney damage in American adults. However, prospective longitudinal studies are needed to establish proper temporal sequence in this relationship.</p>\",\"PeriodicalId\":13831,\"journal\":{\"name\":\"International Journal of Chronic Diseases\",\"volume\":\"2018 \",\"pages\":\"1382705\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-02-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845497/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Chronic Diseases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/2018/1382705\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/1382705","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目标:本研究的目标是估算美国成人高血压患者使用五类降压药与慢性肾脏病(CKD)分期之间关系的变化:本研究的目的是估算美国成人高血压患者使用五类降压药与慢性肾脏病(CKD)分期之间关系的变化:方法:采用美国国家健康与营养调查(NHANES)1999-2012 年的数据集,最终分析样本为 3,045 名参与者。使用 NHANES 调查设计权重计算人口患病率估计值。推理分析采用二项逻辑回归模型:2009-2012年,接受血管紧张素受体阻滞剂(ARB)治疗的患者与未接受ARB治疗的患者相比,CKD晚期(3、4和5期合并)与早期(1和2期合并)的几率明显更高(调整后的几率比(95%置信区间)=2.52(1.32-4.80))。从1999年到2012年,使用ARB多联疗法的患者和使用ARB治疗白蛋白尿的患者之间的这种关系显著增加(p = 0.0023):结论:使用 ARB 作为附加疗法对高血压进行积极的药物治疗可能会加速美国成年人的肾脏损伤。然而,需要进行前瞻性纵向研究,以确定这种关系的适当时间顺序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Antihypertensive Medications and Change in Stages of Chronic Kidney Disease.

Antihypertensive Medications and Change in Stages of Chronic Kidney Disease.

Antihypertensive Medications and Change in Stages of Chronic Kidney Disease.

Objectives: The goal of this study is to estimate the change in the relationships between use of five classes of antihypertensive medications and stages of Chronic Kidney Disease (CKD) in American adults treated for hypertension.

Methods: The US National Health and Nutrition Examination Survey (NHANES) data sets 1999-2012 were used with the final analytical sample of 3,045 participants. Population prevalence estimates were calculated using the NHANES survey design weights. Inferential analyses were done with binomial logistic regression models.

Results: The odds of advanced (3, 4, and 5 combined) versus early CKD stages (1 and 2 combined) were significantly higher among patients treated with Angiotensin Receptor Blockers (ARB) versus those not treated with ARB in 2009-2012 (adjusted odds ratio (95% confidence interval) = 2.52 (1.32-4.80)). From 1999 to 2012, the increase in this relationship was significant (p = 0.0023) for users of ARB polytherapy and in users of ARB in patients with albuminuria (p = 0.0031).

Conclusion: Aggressive pharmacological management of hypertension with ARB as add-on therapy may have accelerated kidney damage in American adults. However, prospective longitudinal studies are needed to establish proper temporal sequence in this relationship.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
2
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信